Back to Journals » OncoTargets and Therapy » Volume 14

Successful Use of Nivolumab in a Patient with Head and Neck Cancer After Allogeneic Bone Marrow Transplantation

Authors Dong X, Lu N, Tong Z, Shi Y

Received 10 June 2020

Accepted for publication 16 January 2021

Published 10 February 2021 Volume 2021:14 Pages 929—936

DOI https://doi.org/10.2147/OTT.S267022

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Sanjay Singh


Supplementary video 1 of "Nivolumab use after bone marrow transplantation" [ID 267022].

Views: 15

Xiaopei Dong, Ning Lu, Zhongsheng Tong, Yehui Shi

Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, People’s Republic of China

Correspondence: Yehui Shi; Zhongsheng Tong
Tianjin Medical University Cancer Institute and Hospital, West Huan-Hu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, People’s Republic of China
Tel +86 18622221183; +86 18622221181
Email shiyehui@tjmuch.com; tongzhongsheng@tjmuch.com

Abstract: Recently, programmed cell death 1(PD-1) inhibitors have shown a significant curative effect in the treatment of most solid cancers and some hematological malignancies. The effects of PD-1 inhibitors in recurrent head and neck squamous cell carcinoma (HNSCC) have also been confirmed. However, there is a lack of reliable clinical evidence to confirm the safety and efficacy of PD-1 inhibitors in patients after allogeneic hematopoietic stem cell transplantation, especially when the patient has a second primary cancer. Generally, graft-versus-host disease (GVHD) is unpredictable among these patients. Here we report the case of a patient who successfully used nivolumab without any GVHD or other immune-related adverse events for HNSCC after allogeneic bone marrow transplantation because of the Philadelphia chromosome-positive T cell acute lymphoblastic leukemia.

Keywords: programmed cell death 1 inhibitor, nivolumab, head and neck squamous cell carcinoma, allogeneic hematopoietic stem cell transplantation, graft-versus-host disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]